Scientific Online Resource System

Izvestia Journal of the Union of Scientists - Varna. Medicine and Ecology Series

Factors responsible for the development of erythropoietin resistance among patients with chronic kidney disease undergoing dialysis

Miroslava Benkova-Petrova


Chronic kidney disease (CKD) is a global socially significant health problem affecting more than 10% of the world's population. One of the complications of CKD is the anemic syndrome, which is associated with reduced quality of life, increased morbidity and mortality and higher treatment costs. A common condition in the treatment of anemia in patients with CKD is erythropoietin resistance. It is one of the most powerful predictors of the risk of cardiovascular accidents and mortality. The aim of the present study was to analyze some of the major factors leading to the development of erythropoietin resistance. In 50 patients undergoing regular hemodialysis treatment at the Clinic of Nephrology of the St. Marina University Hospital, Varna were studied demographic indicators, levels of serum iron, TIBC, TSAT (transferrin saturation), URR, ERI, CRP and iPTH.


erythropoietin resistance, chronic kidney disease, hemodialysis, iron deficiency

Full Text


Ашикова К. Различна ли е резистентността на хемодиализните пациенти към еритропетин-стимулиращи агенти (ЕСА) при лечение на ренална анемия в зависимост от това дали преди хемодиализа болните са лекувани с ЕСА? Нефрология, диализа и токсикология, брой 3,2020, 12-13

Манолов В, Хаджидекова С., Грозданова Р., Обмяна на желязото желязото и атеросклеротични атеросклеротични промени при пациенти пациенти с бъбречно бъбречно заболяване. Съвременна медицина 62(2)2018, 47-62

Astor BC, Coresh J, Heiss G, Pettitt D. Kidney function and anemia as risk factors for coronary heart disease and mortality: the atherosclerosis risk in communities (ARIC) study. Am Hear J. (2006) 151:492–500. doi: 10.1016/j.ahj.2005.03.055

Aoun M, Karam R, Sleilaty G, Antoun L, Ammar W, Barretti P. Iron deficiency across chronic kidney disease stages: is there a reverse gender pattern? PLoS One. 2018;13(1):e0191541. doi:10.1371/journal.pone.01915415.

Chronic Kidney Disease Prognosis Consortium. Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010

Elliott J, Mishler D, Agarwal R: Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009, 16(2):94–100.

Elton Jonh, Freitas Santos, Raimunda Sheyla Carneiro Dias, Janielle Ferreira de Brito Lima, Natalino Salgado Filho Alcione Miranda dos Santos. Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives, Int J Nephrol Renovasc Dis. 2020; 13: 231–237. Published online 2020 Oct 8. doi: 10.2147/IJNRD.S239151;

Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol. 2010;5(4):576–81

Greenwood RN, Ronco C, Gastaldon F et al. Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance. Kidney Int 2003; 64: S78–S86

Hazin MAA Anemia in chronic kidney disease. Rev Assoc Med Bras (1992). 2020 Jan 13; 66Suppl 1(Suppl 1):s55-s58.;

Jacobs C, Frei D, Perkins AC: Results of the European survey on anaemia management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005, 20(Suppl 3):iii3–iii24

Khankin Е., Mutter W,Tamez H., Yuan H-T, Karumanchi A., Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease PLoS One. 2010; 5(2): e9246.Published online 2010 Feb 16. doi: 10.1371/journal.pone.0009246;

Kidney Disease Improving global outcomes Anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335. doi:10.1038/ kisup.2012.37.

Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077–1083.

Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. (2006) 69:560–4. doi: 10.1038/

Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano RCP. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin. (2006) 22:1929–37. doi: 10.1185/030079906X132541

Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, et al: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004, 19(Suppl 2):ii1–ii47

Lopez-Gomez JM, Portoles JM, Aljama P: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008, 111:S75–S81.

Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345. doi:10.1186/s12882-017-0688-1

Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant. 2001;16(1):111–4

Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm. (2005) 11:565–74. doi: 10.18553/jmcp.2005.11.7.565.

Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Rizza GM, et al: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011, 26(8):2641–2648

Rao DS, Shih M, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993;328(3):171–5

Schneider A., Schneider M., Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes BMC Nephrology 2013, 14:67

ZhangY, ThamerM,StefanikK, KaufmanJ, CotterDJ. Epoetin requirements predict mortality in hemodialysis patients. AmJKidney Dis.2004;44:866-876



Font Size